|
|
Volumn 24, Issue 5, 2006, Pages 478-
|
|
Tuft's report backs FDA fast-track, but post-marketing concerns loom
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GEFITINIB;
PACLITAXEL;
PACLITAXEL POLIGLUMEX;
ROFECOXIB;
UNCLASSIFIED DRUG;
AIDS PATIENT;
ANTINEOPLASTIC ACTIVITY;
BIOTECHNOLOGY;
CANCER;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LUNG CANCER;
NOTE;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
BIOTECHNOLOGY;
CLINICAL TRIALS;
DRUG APPROVAL;
HUMANS;
PRODUCT SURVEILLANCE, POSTMARKETING;
TIME FACTORS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
HUMAN IMMUNODEFICIENCY VIRUS;
|
|
EID: 33646537811
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0506-478 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
